<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934
Date of report (Date of earliest event reported): December 11, 2000
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-19731 94-3047598
(State of jurisdiction) (Commission File No.) (IRS Employer
Identification No.)
333 Lakeside Drive,
Foster City, CA 94404
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (650) 574-3000
<PAGE>
Item 5. OTHER EVENTS
On December 11, 2000, Gilead Sciences, Inc. announced
that it intends to sell to certain initial purchasers $250.0
million of convertible subordinated notes ($300.0 million if
the initial purchasers'over-allotment option is exercised in
full). A press release relating to the notes is attached
hereto as Exhibit 99.1.
Item 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND
EXHIBITS
(c) Exhibits
99.1 Press Release dated December 11, 2000
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GILEAD SCIENCES, INC.
Dated: December 11, 2000 By: /s/ Mark L. Perry
-----------------------------
Mark L. Perry
Executive Vice President,
Operations
<PAGE>
EXHIBIT INDEX
Exhibit
Number Description
------- -----------
99.1 Press Release titled "Gilead Sciences Initiates Private
Placement of Convertible Subordinated Notes" dated
December 11, 2000.
